Hoth Therapeutics Inc Stock Price, News & Analysis

Hoth Therapeutics (NASDAQ: HOTH) updated shareholders on its COVID-19 initiatives and dermatological therapies. The company is advancing its pipeline, including the BioLexa platform for atopic dermatitis, and submitted for ethics board approval in Australia for clinical trials. Hoth licensed VNLG-152 for dermatological diseases and partnered with George Washington University to explore WEG-232 for Erlotinib side effects. Notably, Hoth is developing a breath-based COVID-19 testing device and a self-assembling vaccine platform, with preclinical testing underway.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) has submitted an ethics approval request to the Bellberry Human Research Ethics Committee in Australia for its upcoming clinical study of BioLexa, aimed at treating atopic dermatitis. The study will be a randomized, double-blind, vehicle-controlled trial assessing the safety, tolerability, pharmacokinetics, and efficacy of BioLexa in patients with mild to moderate atopic dermatitis. This marks a significant step in Hoth's clinical development program, as stated by CEO Robb Knie, highlighting the company's commitment to advancing innovative therapies.

Hoth Therapeutics, Inc. (NASDAQ:HOTH) announced its participation in LD Micro's Zooming with LD on August 11, 2020, at 8 AM PDT. CEO Robb Knie will present an overview of the company's operations and recent advancements, particularly the development of a breath-based COVID-19 mobile testing device. This virtual presentation marks an important opportunity for Hoth to showcase its innovations in biopharmaceuticals, especially in treating dermatological disorders and COVID-19 vaccine development. For access, use the password HOTHwithLD.

Hoth Therapeutics, Inc. (NASDAQ:HOTH) will present at LD Micro's Zooming with LD on August 11, 2020. CEO Robb Knie will discuss the company's recent developments, including a license for a breath-based COVID-19 testing device. The presentation is set for 8 AM PDT and will take place virtually via Zoom, accessible with the password HOTHwithLD. Hoth Therapeutics is focused on developing innovative therapies for dermatological conditions and is also advancing two COVID-19 vaccine prospects.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) has announced a licensing agreement for a medical device that enables rapid COVID-19 diagnostics via breath samples. Developed in collaboration with George Washington University, the device utilizes nanotechnology and AI to deliver immediate results, allowing public health professionals to conduct point-of-care testing efficiently. The initiative aims to create real-time data tracking for COVID-19 infections, enhancing public health responses during the pandemic. CEO Robb Knie emphasized the device's potential to mitigate COVID-19 spread significantly.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) has signed a licensing agreement with Isoprene Pharmaceuticals, Inc. to acquire rights to VNLG-152, a novel retinamide for dermatological diseases. This agreement follows an earlier Letter of Intent and enables Hoth to receive royalties from Isoprene’s usage of VNLG-152 in oncology. UMB researchers have validated RAMBAs’ effectiveness against breast and prostate cancer, showing superior effects compared to approved retinoids. Hoth aims to address dermatological disorders while mitigating adverse effects associated with traditional retinoid therapies.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced a sponsored research agreement with Virginia Commonwealth University (VCU) aimed at developing a potential treatment for COVID-19. Led by Dr. Michael Peters, the research focuses on optimizing peptide biomimetics to enhance their binding rates to the SARS-CoV-2 spike protein. The project is expected to leverage advanced computational resources to improve peptide stability and efficacy. Hoth has an exclusive license for this innovative COVID-19 therapeutic.

Hoth Therapeutics (NASDAQ: HOTH) announced an expanded research agreement with George Washington University to investigate WEG232 for treating dermatological side effects related to chemotherapy and immunotherapy. The company aims to request a Pre-IND meeting with the FDA by year-end. WEG232 has shown promise in reducing erlotinib-induced facial rash by approximately 71%. Future studies will explore optimal application timing and its effects on inflammation. CEO Robb Knie expressed optimism about advancing this much-needed therapeutic for cancer patients.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced the publication of a white paper by Scientific Advisory Board member Dr. Michael H. Peters, detailing mappings of the COVID-19 virus spike protein. The company has licensed exclusive technology from VCU for a novel peptide therapeutic aimed at preventing spike protein binding, potentially slowing COVID-19 transmission. This peptide binds with high affinity to the SARS-CoV-2 spike protein, blocking its attachment to human cells. Hoth is also advancing its pipeline focused on dermatological disorders and COVID-19 vaccine prospects.